Ashvattha Therapeutics and the case for a needle nowhere near the eye

There is a peculiar intimacy to modern retinal medicine. To preserve sight, a patient may have to visit a clinic repeatedly for a drug delivered by needle directly into the eye. The procedure is routine for the specialist; for the patient, routine can still mean arranging a ride, clearing an afternoon and coming back a few weeks later. If both eyes are affected, the calendar becomes a second illness.

Ashvattha Therapeutics has organized its leading experiment around that calendar. The Redwood City company is testing migaldendranib, or MGB, a drug given by injection under the skin. Its carrier is designed to move through the bloodstream, cross the blood-retinal barrier where disease has made tissue inflamed, and enter activated cells in the retina. The commercial proposition is almost offensively simple: one administration could work in both eyes and reduce the need for injections into either one.

The appointment is part of the disease

Wet age-related macular degeneration and diabetic macular edema have different causes, but both can produce abnormal fluid in the retina and threaten vision. Doctors often treat them with medicines that block vascular endothelial growth factor, or VEGF. These anti-VEGF drugs have changed retinal care. They also tend to require repeat intravitreal injections in the physician's office. Ashvattha is therefore competing against a proven treatment habit, not an empty shelf.

Its proposed alternative does not ask a retinal specialist to stop monitoring patients. It asks whether the drug can be delivered in a less demanding way. MGB pairs a VEGF receptor tyrosine kinase inhibitor with a hydroxyl dendrimer, a branched molecular carrier. Ashvattha says the carrier preferentially enters activated macrophages, microglia and stressed retinal pigment epithelial cells in inflamed regions, where the drug can reduce VEGF expression. That is a different route and a different point of attack from giving an anti-VEGF drug directly into each eye.

The 40-week readout, announced in September 2025, is the figure that makes the idea worth discussing. The company reported an annualized reduction from 8.4 to 1.6 injections in study eyes, with reductions of 78.6% for the diabetic macular edema subgroup and 83.4% for the wet AMD subgroup. Fellow eyes went from 8.3 to 0.9. Ashvattha also reported no MGB treatment-related ocular or systemic serious adverse events in that study and improvements in some vision and anatomy measures. These are encouraging observations from a Phase 2 study of previously anti-VEGF-treated patients. They do not establish that a take-home drug is approved, or that it will outperform the office routine in a larger trial.

“What we're focused on is trying to remove the need to have intravitreal injections, and have an at home administered product.”Jeffrey Cleland, speaking to Ophthalmology Times in 2024

A tiny courier with a long family tree

Ashvattha's technology began far from a product launch. Kannan Rangaramanujam and Sujatha Kannan developed the underlying dendrimer work through research groups at Johns Hopkins and Wayne State University. Jeffrey Cleland brought drug-development experience, including time at Genentech and earlier ophthalmology work, to the company founded in 2015. Natural Capital incubated it. The company licensed the platform and built a portfolio around a recurring observation: activated inflammatory cells appear to take up its hydroxyl dendrimers in ways healthy cells often do not.

The word “platform” is used liberally in biotech. Here it has a concrete meaning: attach a different active molecule to the dendrimer and test whether the same targeting behavior can deliver it to a different diseased tissue. OP-101, an N-acetylcysteine conjugate, was studied in severe COVID-19 hyperinflammation. A small Phase 2a trial reported changes in inflammatory and neurological injury markers and a survival signal; the results were published in Science Translational Medicine in 2022. The company also developed PET imaging tracers, including 18F-OP-801, to follow inflammatory activity in the brain. These programs demonstrate the breadth of the idea, though they sit at different stages of evidence and are not sold medicines.

What the bet costs

A drug-delivery theory needs years of chemistry, toxicology, manufacturing and trials before a patient can rely on it. Ashvattha announced a $69 million Series B in 2022, led by Huadong Medicine Investment Holding, with Natural Capital, Plum Alley and Tribe Capital participating. In a separate deal, Huadong received rights to develop and commercialize several candidates in China and parts of Southeast Asia, promising up to $45 million in development advances and a 10% royalty on net sales of licensed products. In January 2025, Tribe Capital led a Series B extension of up to $50 million. “Up to” matters: it is a financing ceiling, not evidence that every dollar has been drawn.

The regional license explains the business model as well as any pitch deck. Ashvattha is spending investor and partner money to create clinical assets. It has no disclosed marketed product or reliable public product revenue. Its immediate customers are, in effect, trial investigators and future pharmaceutical partners; the people who stand to benefit are patients and retina practices, if the clinical and regulatory work succeeds. A medicine that lowers office injection burden could also interest health systems and payers, but its price and eventual coverage terms are unknown.

There is a revealing change in the company's public emphasis. The 2022 financing announcement ranged across severe COVID-19, ALS and retinal disease. Its current pipeline page puts migaldendranib at the center. That does not prove the earlier programs failed. It does show where Ashvattha has chosen to place its clearest clinical and commercial argument: a measurable reduction in the number of needles delivered to eyes. The second eye is especially persuasive. A treatment circulating through the body has a plausible advantage when disease is bilateral, provided it can reach the retina without causing unacceptable effects elsewhere.

A clever route still needs a hard trial

The strongest feature of Ashvattha's work is also the obvious question. Systemic delivery is convenient only if it is safe and reliably effective. The company reported no treatment-related serious ocular or systemic adverse events in its 40-week Phase 2 trial, but larger studies are built to expose rare problems and to test efficacy against a predefined endpoint. Ashvattha said in October 2025 that the FDA agreed with its Phase 2b/3 design, including a 12-month primary efficacy endpoint and two studies under one protocol. Agreement on a plan is progress, not approval of the drug.

The practical lesson is bigger than nanomedicine. Start with the patient's recurring inconvenience and make it measurable. Ashvattha did not merely say “better delivery”; it counted supplemental intravitreal injections, checked vision and retinal anatomy, and looked at both eyes. Another drug developer could copy that discipline even with entirely different chemistry: define the appointment, procedure or monitoring burden the product claims to remove, then collect evidence that the burden fell without giving back the health benefit.

It may still be that a proven office injection remains the better choice for some patients, or that MGB's Phase 2 signal weakens in a larger, more varied population. For now the company has done something useful: it has turned an abstract question about molecular targeting into a very ordinary question about a person's month. How many times must they go back to the eye clinic? The answer will be written in the next trial, not the next adjective.